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Background. Diagnosis and management of Clostridium diﬃcile infection (CDI) rely upon clinical assessments and diagnostic
studies. Among diagnostic tests, lower gastrointestinal (GI) endoscopy in the setting of CDI remains controversial. Objective.T o
describe the role of lower endoscopy in CDI management. Methods. Retrospective study of lower endoscopies in CDI at four
metropolitan hospitals, July 2005 through December 2007. Results. Of 1760 CDI inpatients, 45 lower endoscopies were performed
on 43 patients. Most common indications were ruling out other etiologies (42%), inconclusive stool studies (36%), and worsening
course (11%). Most endoscopies (73%) had positive ﬁndings, including pseudomembranous colitis (49%) and nonspeciﬁc colitis
(24%). Biopsies were performed in 31 cases, more with nonspeciﬁc colitis (10/11, 92%) compared to pseudomembranous colitis
(14/22, 64%). Conclusion. While not recommended as a primary screening tool, lower GI endoscopy can add valuable information
in CDI when other colonic pathologies may exist, studies are inconclusive, or clinical status worsens.
1.Introduction
Clostridium diﬃcile infection (CDI) is a signiﬁcant public
health problem due to its association with antibiotic use and
healthcare settings, increasing overall incidence, evolving ep-
idemiology, and high associated health care costs. For any
individual patient with symptomatic CDI, the spectrum of
disease can vary widely. While initial treatment is eﬀective in
most cases, some cases are highly complex including patients
with recalcitrant or recurrent disease [1], infections caused
by increasingly virulent strains of Clostridium diﬃcile (C.
diﬃcile) that are unresponsive to traditional medical therapy
[2–4], and patients with fulminant colitis requiring surgery
[5–10].
Stool studies like enzyme immunoassays for C. diﬃcile
toxins [3, 11] have improved our diagnostic abilities with
CDI. The diagnosis, management, and treatment of CDI,
particularly in the acute inpatient setting, rely upon a
combination of ongoing clinical assessments and diagnostic
studies.Lowergastrointestinal(GI)endoscopy,eitherﬂexible
sigmoidoscopy or colonoscopy, can be used to (1) visualize
the colon looking for inﬂammation or for the presence of
pseudomembranes and (2) to obtain tissue and stool for
diagnostic purposes.
The optimal role of the lower GI endoscopy in the setting
of CDI remains poorly deﬁned and controversial. In the
late 1970s and 1980s, some authors stressed the importance
of endoscopy as a diagnostic tool [12, 13]. In the 1990s,
with the improvement in the speed and reliability of the
microbiologic diagnostic tests, it was thought to be less
useful due to the cost and the relative lack of sensitivity of
endoscopy as a general screening tool. As such, lower GI
endoscopy began to play a secondary role in the workup of
antibiotic-associated diarrhea [14].
Over the past decade, the pattern of CDI has changed
and evolved. CDI has become a more frequent and severe2 Gastroenterology Research and Practice
disease that is increasingly refractory to standard therapy
and likely to relapse [2, 3, 15]. This more severe version
of the disease has been associated with the use of relatively
new antibiotics like ﬂuoroquinolones [2–4, 16, 17]a n d
an e ws t r a i no fC. diﬃcile known as BI/NAP1/ribotype
027, which was ﬁrst reported during outbreaks in Quebec,
Canada in the early 2000s [16]. There is only one study
that has looked at the role of lower GI endoscopy during
this later epidemiological presentation [18], and the authors
concluded that lower GI endoscopy was superior to the
exclusive use of C. diﬃcile cytotoxin testing of stools in
the subgroup of patients with pseudomembranous colitis
and that ﬂexible endoscopy should be considered in all
hospitalized patients with diarrhea in whom the stool test for
C. diﬃcile cytotoxin and enteric pathogens is negative but a
high level of clinical suspicion remains.
The goal of this paper is to describe the use and role
of ﬂexible lower GI endoscopy with CDI in an inpatient
setting including exact indication for the study, utility of the
endoscopy, histopathological ﬁndings, and outcomes.
2. Methods
Data were collected from four metropolitan hospitals
(Fairview Health Services in Minnesota, USA), including the
University of Minnesota Medical Center (July 2005 through
December 2007), on all inpatients with a documented
diagnosis of CDI (ICD-9CM code 008.45) and a lower
GI endoscopy (ICD-9 procedure codes for sigmoidoscopy
(45.24) or colonoscopy (45.22, 45.23, 45.25, 45.42, 45.43))
during the same admission. We included patients who
underwent lower GI endoscopy for an indication related to
assisting with the diagnosis, followup, or treatment of CDI.
Those patients with CDI who had endoscopy performed
for other indications like rectal bleeding or chronic anemia
were excluded as were patients with a known history of
inﬂammatory bowel disease. Demographic data, patient
comorbidities, and known risk factors for the development
of CDI were recorded including current or recent hospital-
ization,ageolderthan65years,recentsurgery,andantibiotic
exposure. History of antibiotic exposure including class of
antibiotic, previous episodes of CDI, the presence or absence
of diarrhea, and characteristics of the diarrhea was also
included as baseline data.
CDI was considered “hospital onset” if the patient devel-
oped symptoms as an inpatient and “community onset” if
the patient was admitted to the hospital with CDI symptoms
that started in the community. Patients were also classiﬁed
as immunosuppressed if the patient had one or more
of the following: chronic systemic corticosteroids, cancer,
HIV/AIDS, or organ transplant. Clinical status at the time
of endoscopy was also recorded including the presence of
fever, leukocytosis, albumin level, presence of septic shock,
and admission to the intensive care unit.
Patient records were carefully reviewed to ascertain how
or if the diagnosis of CDI had been established at the time of
lower GI endoscopy, including clinical diagnosis, outcomes
of stool assays (C. diﬃcile toxins A/B, C. diﬃcile toxin A, and
C. diﬃcile culture), and use of imaging studies (particularly
use of abdominal CT scan). With respect to lower GI
endoscopy, the speciﬁc clinical indication was determined
and classiﬁed into categories: ruling out other etiologies,
high clinical suspicion despite inconclusive stools studies
(negative or pending), worsening course of disease, and
therapeutic reasons (e.g., bowel decompression, placement
of rectal tube, medication enemas). Lower GI endoscopy
was considered to have been performed to rule out other
etiologies when the CDI diagnosis was already established
(clinical suspicion and C. diﬃcile toxin A or A/B (+), or
C. diﬃcile culture (+)) but there was the need to rule
out other etiologies due to other clinical factors where
additional colonic pathology could be occurring simulta-
neously, including persistent symptoms, bloody diarrhea
or immunosuppression (risk of Cytomegalovirus (CMV)
colitis and/or graft versus host disease (GVHD) specially in
transplant patients).
Endoscopic ﬁndings, biopsy results, initial therapy, and
postprocedure therapy after performing endoscopy and
response to treatment were also collected. Antibiotic therapy
with metronidazole orally or intravenously, vancomycin
orally or with enemas, and/or rifaximin orally was also
determined. Surgery as initial or later therapy and recur-
rence/relapse of the disease were also recorded.
Comparisons between groups of patients were made
using analysis of variance, chi-square statistics, Fisher exact
test, and Student’s t-test as appropriate. Signiﬁcance was
accepted at the 5% level. University of Minnesota Institu-
tional Review Board approval was obtained and informed
consent waived for this study.
3. Results
3.1. Patient Demographics, Comorbidities, Risk Factors, and
Clinical Presentation. Over the two-and-a-half-year period,
there were 1760 total cases of inpatient CDI of which 43
inpatients (mean age 59, 53% female) underwent 45 total
lower GI endoscopy studies to assist with the diagnosis
and/or management of CDI. A summary of patient charac-
teristics, comorbidities, risk factors, and clinical presentation
is included in Table 1. The most important comorbidities
were cardiac disease (65%), immunosuppression (56%),
pulmonary disease (40%), diabetes (26%), and chronic
renal failure (26%). The use of steroids (49%) was the
most important cause for immunosuppression, followed
by cancer (30%) and transplant (28%). Of 12 patients
with transplants, 6 (50%) had bone marrow transplants, 3
(25%) lung transplants, and 3 (25%) kidney and/or pancreas
transplant. Of note, HIV/AIDS was considered as one cause
of immunosuppression, but we did not have any patient with
this condition in our sample.
Most of the patients were found to have exposure to
antibiotics (91%) before developing CDI. Fluoroquinolones
were most often the inciting antibiotic (57%), followed
by cephalosporins (13%). A history of recent surgery, GI
or non-GI, was found in 15 patients (35%). There were
16 (37%) patients with recurrent disease, including 10
(62.5%) with persistent disease and 6 (37.5%) with delayed
recurrence.Gastroenterology Research and Practice 3
Table 1: Patients demographics, comorbidities, risk factors, and clinical presentation.
All patients (n = 43) Recurrent disease (n = 16) Primary disease (n = 27)
Sex, M/F 20/23 6/10 14/13
Age, mean, y 59 62 58
Length of stay, d 12 14 11
Comorbidities
Cardiac disease 28 (65%) 12 (75%) 16 (59%)
Immunosuppression 24 (56%) 11 (69%) 13 (48%)
Steroids 21 (49%) 11 (69%) 10 (37%)
Cancer 13 (30%) 7 (44%) 6 (22%)
Transplant 12 (28%) 6 (38%) 6 (22%)
Pulmonary disease 17 (40%) 6 (38%) 11 (41%)
Diabetes 11 (26%) 7 (44%) 4 (15%)
Chronic renal failure 11 (26%) 5 (31%) 6 (22%)
Risk factors
Antibiotic exposure 39 (91%) 13 (81%) 26 (96%)
Current/recent hosp. 36 (84%) 16 (100%) 20 (74%)
Age >65 17 (40%) 6 (38%) 11 (41%)
Recent surgery 15 (35%) 3 (19%) 12 (44%)
Presentation
Community∗ 36 (84%) 15 (94%) 21 (78%)
Hospital∗ 7 (16%) 1 (6%) 6 (22%)
Ileus, distended abdomen 1 (2%) 1 (6%) —
Diarrhea 42 (98%) 15 (94%) 27 (100%)
Presence of fever 18 (42%) 4 (25%) 14 (52%)
Septic shock 7 (16%) 3 (19%) 4 (15%)
ICU admission 8 (19%) 3 (19%) 5 (19%)
WBC >11.0 or <4.0 29 (67%) 10 (63%) 19 (70%)
Albumin <3.2 20 (47%) 9 (56%) 11 (41%)
∗Onset of CDI: in the community, or in the hospital while inpatient.
While 36 patients (84%) had CDI which started prior to
hospitalization, in the community, 29 (81%) had a history
of a recent hospitalization before developing CDI. Seven
patients (16%) were admitted to the hospital for other
reasons and developed CDI during the course of their stay
(hospital onset). While one patient presented with an ileus,
all others had diarrhea at presentation. Fever was present in
18(42%),abnormalwhitebloodcountin29(67%),albumin
waslessthan3.2mg/dLin20(47%),septicshockin7(16%),
and ICU admission in 8 (19%).
3.2. Use of Ancillary Studies. Overall, only 22 (51%) patients
had positive C. diﬃcile toxins A or A/B, with 13 of 22 (59%)
with a positive C. diﬃcile stool culture. From the 21 patients
with negative C. diﬃcile t o x i n sAo rA / B ,1 2o f2 1( 5 7 % )h a d
ap o s i t i v eC. diﬃcile stool culture.
Therewere9patientswithbothnegativeC.diﬃciletoxins
Ao rA / Ba n dC. diﬃcile stool culture. In this subgroup
of patients, the lower endoscopy was used as a diagnostic
tool. Lower endoscopy was positive in 8/9 (88%) patients,
with PMC in 6 cases and non-speciﬁc colitis in 2 cases. The
biopsies of these 2 nonspeciﬁc colitis cases showed 1 PMC
and 1 ischemic colitis. The only patient with both negative
C. diﬃcile toxins A or A/B and C. diﬃcile stool culture that
had negative lower endoscopy was a bone marrow transplant
patient. This same patient had another endoscopy later in his
hospital stay that showed PMC.
Of the 16 (37%) patients with recurrent disease there
were 11 (69%) with negative culture or toxin stool tests,
including 9 (56%) recurrent patients with a negative C.
diﬃcile toxin test (four with a negative culture) and two
negative C. diﬃcile culture results in the 7 (44%) recurrent
patients with a positive C. diﬃcile toxin test. In the 27 (63%)
patients with a new diagnosis of CDI, 19 (70%) had one
or more negative tests, including 12 (44%) patients with a
negative C. diﬃcile t o x i nt e s t( 5wi t han e g a t i v es t o o lc u l t u r e )
and seven negative C. diﬃcile culture results in the 15 (56%)
patients with a positive C. diﬃcile toxin test.
An abdominal CT scan was performed in 28 (65%)
patients. CT scan ﬁndings were positive for colonic pathol-
ogy in 25 (89%) patients, including pancolitis in 15 (54%)
and segmental colitis in 10 (36%). Ascites was observed in 4
patients that had pancolitis. Free air was not found on any
abdominal CT scan.4 Gastroenterology Research and Practice
Table 2: Lower GI endoscopy indications.
Overall N = 45 Recurrent disease N = 17 Primary disease N = 28
Rule out other etiologies 19 (42%) 6 13
Immunosuppression 4 (9%) 1 3
Bloody diarrhea 4 (9%) — 4
Ongoing symptoms despite therapy 8 (18%) 4 4
Other 3 (7%) 1 2
C. diﬃcile studies inconclusive 16 (35%) 8 8
Worsening clinical status 5 (11%) 2 3
Followup of known colonic pathology∗ 4( 9 % ) ∗ 13
Therapy+ 1( 2 % ) — 1
∗History of microscopic colitis (n = 2), followup of colonic surgery (n = 2). +Bowel decompression.
Table 3: Lower GI endoscopy ﬁndings and histopathologic results on biopsy.
Endoscopy Findings Histopathological results
Overall
N = 45
Biopsy
N = 31
PMC
N = 13
Infect. colitis
N = 5
Indeterminate
or other colitis
N = 7
Other
N = 2∗
Normal
N = 4
PMC 22 (49%) 14 12 1 — 1 —
NSC 11 (24%) 10 1 4 5 — —
Negative 12 (27%) 7 — — 2 1 4
PMC: Pseudomembranous colitis. NSC: Nondiagnostic or indeterminate nonspeciﬁc colitis or inﬂammation without pseudomembranes. Negative: normal
mucosa or no inﬂammation.
∗One patient with concurrent CMV colitis (biopsy)/CDI had showed PMC at endoscopy. The other patient with negative endoscopy had GVHD at biopsy.
3.3. Indications of Lower GI Endoscopy. Of 45 lower GI endo-
scopic procedures, 28 (62%) ﬂexible sigmoidoscopies and 17
(38%) colonoscopies were performed in 43 patients. Two
patients had two endoscopies performed during the same
hospital stay. Indications for these studies are summarized in
Table 2. The most common indication was ruling out other
colonic etiologies in 19 (42%) patients, including (a) four
immunosuppressed patients where there was a need to rule
outCMVcolitisand/orGVHD,(b)fourpatientswithbloody
diarrhea where inﬂammatory bowel disease, ischemic colitis,
or malignancy was suspected, and (c) eight patients with
persistent diarrhea despite medical treatment for CDI.
Another16(36%)patientsunderwentlowerGIendosco-
py due to inconclusive C. diﬃcile studies, particularly when
C. diﬃcile toxins A and A/B were either negative or pending.
Of these, 14 patients had a high clinical suspicion for CDI,
but C. diﬃcile toxins were negative and cultures pending at
the time of lower GI endoscopy, and 2 patients had recurrent
symptoms where lower GI endoscopy was performed prior
to any stool study results due to a suspicious CT scan.
There were 5 (11%) patients who underwent lower
endoscopy in the setting of a worsening clinical course
including progression to septic shock or multisystem organ
f a i l u r e .O ft h e s e ,t w oﬂ e x i b l es c o p e sw e r ep e r f o r m e df o l l o w -
ing surgery (subtotal colectomy) for CDI to assess the rectal
stump in the setting of multisystem organ failure. Another
four (9%) lower endoscopies were indicated to followup on
a known disease/condition, including two with a history of
microscopic colitis and another two in the postoperative
period following colectomy. One patient underwent lower
GI endoscopy for bowel decompression (therapeutic) with
the ﬂexible endoscopy demonstrating pseudomembranous
colitis.
3.4. Lower GI Endoscopy Findings and Pathology. Lower GI
endoscopy demonstrated pseudomembranous colitis in 22
(49%) patients, nonspeciﬁc colitis or inﬂammation without
pseudomembranes in 11 (24%), and normal mucosa in
12 (27%) patients (Table 3). There were no complications
associated with lower GI endoscopy like perforations or
major bleeding after biopsy. In the 31 biopsies performed,
histology demonstrated pseudomembranous colitis in 13
(42%) and infectious colitis in 5 (16%). Biopsy was done less
commonly when the endoscopy showed visible pseudomem-
branous colitis (14 of 22) than when it showed nonspeciﬁc
colitis or inﬂammation without pseudomembranes (10 of
11), although this was not statistically signiﬁcant (63.6%
versus 90.9%, P = 0.09).
3.5. Outcomes following Lower GI Endoscopy. Table 4 sum-
marizes alterations in CDI-directed therapy following lower
GI endoscopy and patient outcomes. Initial therapy was
metronidazole (oral or intravenous) in 29 patients, oral
or enema administration of vancomycin in 4 patients, and
vancomycin and metronidazole in 10 patients at the time of
lower GI endoscopy. Following endoscopy, medical therapy
was not changed in 27, escalated in 11, decreased in 2,
and changed to surgical treatment in 3. Subtotal colectomy
and ileostomy were performed in 3 patients with fulminantGastroenterology Research and Practice 5
Table 4: Treatment: initial therapy, course/followup, overall outcome.
Initial therapy
Overall
N = 43
∗
Metronidazole
N = 29
Vancomycin
N = 4
Vanco + metronidazole
N = 10
Treatment following lower GI endoscopy
No change in therapy∗ 27 (60%) 18 4 5
Escalating medical therapy 11 (26%) 10 — 1
Decreasing medical therapy 2 (5%) — — 2
Surgery+ 3( 7 % ) 1 — 2
Outcome
Resolved 28 (65%) 20 2 6
Recurrent disease 11 (26%) 9 1 1
Death 4 (9%) — 1 3
∗One patient in the no change in therapy group was on oral vancomycin (allergic to metronidazole) with bone marrow transplant and C. diﬃcile,C M V ,a n d
graft versus host disease. The ﬁrst endoscopy demonstrated a negative biopsy, and there was no change in therapy. The patient did not improve, and a second
endoscopy was performed demonstrating PMC and on biopsy CMV colitis. He progressed to multisystem organ failure and died.
+Onepatientinthesurgerycategoryhadtwoendoscopies:oneendoscopypriortosurgeryandoneendoscopyaftersurgerytoassesstheileostomyandmucus
ﬁstulotomy.
colitis. Two patients resolved CDI following surgery with
no recurrent episodes. One patient following colectomy
progressedtomultisystemorganfailure,followedbycomfort
care and death. CDI completely resolved in 28 out of 43
patients (65%); 11 (26%) patients had recurrent disease, and
4 (9%) patients progressed to multisystem organ failure and
died after comfort care/withdrawal of support.
4. Discussion
The management of CDI, particularly in the hospitalized
patient in the acute setting, relies upon a combination of
ongoing clinical assessments and diagnostic studies. Among
thesetests,lowerGIendoscopy,eitherﬂexiblesigmoidoscopy
or colonoscopy, can be used both to visualize the colon
and to obtain tissue for diagnostic purposes. Its role in the
management of CDI, however, has remained controversial
and poorly deﬁned. In this study we retrospectively analyzed
inpatients with CDI who underwent lower GI endoscopy
during the same admission to assist in the diagnosis,
followup, or treatment of CDI.
There are several limitations of this study, including
its retrospective nature and coverage of only the inpatient
setting. While our use of ICD-9 codes may slightly under-
estimate the use of lower GI endoscopy with CDI, previous
studies have demonstrated that ICD-9 CM codes closely
approximate true CDI, especially in symptomatic patients
where test results are available at discharge and can be
therefore used as a reasonable alternative to microbiological
data for cohort identiﬁcation [19]. Another limitation of this
study is the use of enzyme toxin assays as the main initial
diagnostic test. Currently, many health care institutions
are moving to use PCR studies for CDI diagnosis. PCR
studies have a much higher sensitivity, lower rate of false
negative results, and faster results availability. This study was
conducted prior the use of PCR as diagnostic test.
Forty-ﬁve lower GI endoscopy procedures were per-
formed in 43 patients over two and half years most often
to rule out additional colonic etiologies, to conﬁrm CDI
when C. diﬃcile stool testing was inconclusive, and to
conﬁrm CDI and response to treatment in the setting of
a worsening clinical course. Similar to previous reports
[14, 20], pseudomembranous colitis was demonstrated in
22 endoscopies (49%), nonspeciﬁc colitis in 11 (24%), and
normal mucosa in 12 (27%).
Historically, in the late 1970s and 1980s, lower GI
endoscopy use in the diagnosis of CDI was encouraged [13],
as the etiological agent for CDI was not identiﬁed until 1978.
In the 1990s, with the availability of the microbiological
diagnostic tests, lower GI endoscopy was considered costly,
invasive, and insensitive. It was relegated to a secondary
role in the workup of antibiotic-associated diarrhea [14, 20].
More recently, CDI patterns have changed and evolved since
the early 2000s, turning to a more frequent and severe
diseasethatisincreasinglyrefractorytostandardtherapyand
more likely to relapse [2, 3, 15]. This more severe version
of the disease is associated with the use of relatively new
antibiotics like ﬂuoroquinolones [2–4, 17, 21]a n dan e w
strain of C. diﬃcile known as BI/NAP1/ribotype 027. One
recent study analyzing the use of lower endoscopy with CDI
[18] suggested that ﬂexible sigmoidoscopy was superior to
stool C. diﬃcile cytotoxin testing in the subgroup of patients
with pseudomembranous colitis.
We found that the most common indication for lower
GI endoscopy in CDI patients was the need to rule out
coexisting pathology with CDI (42%) where the CDI
diagnosis was already established prior to the performance
of the lower GI endoscopy. This was particularly true in
solid organ transplant and bone marrow transplant patients,
whereconditionslikegraftversushostdiseaseorCMVcolitis
can occur simultaneously with CDI and require signiﬁcantly
diﬀerent approach in treatment and management [22]. With
solid organ transplant patients, CDI is one of the most
common causes of diarrhea and has been increasing in
incidence since the early 2000s [23]. Moreover, in certain
populations, particularly lung transplant patients who are6 Gastroenterology Research and Practice
exposed regularly to antibiotics, CDI can progress into a life-
threatening condition with fulminant colitis [24].
In addition, a subset of patients with CDI presented
with concomitant bloody diarrhea which led to lower GI
endoscopy to rule out other etiologies including ischemic
colitis, inﬂammatory bowel disease, or severe pseudomem-
branous colitis. In patients with CDI and a high clini-
cal suspicion for IBD, several etiologic processes may be
occurring: an IBD ﬂare with colonization by C. diﬃcile,
superimposed CDI without IBD ﬂare, or both processes
occurring simultaneously [25]. We did not observe a new
diagnosis of IBD in this setting. Most of these cases
(9/10) represented a severe presentation of CDI (with six
having pseudomembranous colitis on endoscopy and three
having nonspeciﬁc colitis). While there have been reports
that patients on immunosuppressive treatments with CDI
typically do not have pseudomembranes [26], we observed
an immunosuppressed patient with bloody diarrhea with
severe pseudomembranes.
We found that lower GI endoscopy was particularly
helpful in conﬁrming the diagnosis of CDI in patients with a
high level of clinical suspicion for CDI but inconclusive stool
tests (either negative or pending). This was consistent with
the prospective ﬁndings of Johal et al. who concluded that,
in this particular subset of patients, ﬂexible sigmoidoscopy
was superior to the stool C. diﬃcile cytotoxin test [18]. This
setting is one where other authors tend to agree on the use of
lower endoscopy as an adjunctive tool for diagnosis of CDI
[18, 27]. Overall in our sample study, only 22 (51%) patients
had positive C. diﬃcile toxins A or A/B. This partially could
be attributed to the nature of our study sample, which only
included patients with CDI that had an endoscopy. Since the
sensitivity of C. diﬃcile toxin A or toxins A/B tests of this
era is 70%-80%, it requires repeat testing and if high clinical
suspicion exists, the initiation of empiric treatment should
be initiated [11]. Of the 21 patients with negative C. diﬃcile
toxins, 15 (71%) had a positive endoscopy, including PMC
in 10 (48%) and nonspeciﬁc colitis/inﬂammation without
pseudomembranes in 5 (24%). There were 9 patients with
both negative C. diﬃcile toxins A or A/B and C. diﬃcile stool
culture. In this subgroup of patients, the lower endoscopy
was used as a diagnostic tool. Lower endoscopy was positive
in 8/9 (88%) patients, with PMC in 6 cases and nonspeciﬁc
colitis in 2 cases. The biopsies of these 2 non speciﬁc colitis
cases showed 1 PMC and 1 ischemic colitis. The only patient
with both negative C. diﬃcile toxins A or A/B and C. diﬃcile
stool culture that had negative lower endoscopy was a bone
marrow transplant patient. This same patient had another
endoscopy later in his hospital stay that showed PMC.
These results conﬁrm the utility of lower endoscopy in this
subgroup of patients.
As a ﬁnal set of indications, lower GI endoscopy was
particularly helpful in cases of worsening clinical course
to conﬁrm fulminant colitis (i.e., need for surgery) or to
conﬁrm the status of other colonic pathology. In our series,
worsening clinical course was the indication for lower GI
endoscopy in 5 (11%) of the patients, mostly as patients were
progressingtosepticshockormultisystemorganfailure.This
indication has particularly high utility in cases of fulminant
colitiswhereadjunctstudiesmaynotbedeﬁnitiveandtimely
treatment is imperative [5, 20]. We also observed 4 (9%)
patients who underwent lower endoscopy in the setting of
known secondary colonic pathology as a study for ongoing
clinical assessment in response to therapy.
5. Conclusion
In summary, endoscopic ﬁndings in our study correlated
with the ﬁndings of other authors that have reported positive
results in ∼70% of CDI cases [11, 14, 20] including pseu-
domembranous colitis (∼50–60%) and nonspeciﬁc colitis or
inﬂammation without pseudomembranes. We observed that
lower GI endoscopy in CDI, when indicated, plays a role not
only as a diagnostic tool but also in the overall management
of the disease. Thus, the most common indication of
lower GI endoscopy in the setting of CDI was to rule
out other colonic pathologies that may be coexisting with
CDI diagnosis and inconclusive C. diﬃcile studies being the
second most common indication.
Disclosure
The authors have no ﬁnancial disclosures to declare.
Acknowledgment
The authors thank Fairview Health Services for ongoing
support of this research.
References
[1] T. Monaghan, T. Boswell, and Y. R. Mahida, “Recent advances
in Clostridium diﬃcile-associated disease,” Gut, vol. 57, no. 6,
pp. 850–860, 2008.
[2] J. G. Bartlett, “Narrative review: the new epidemic of Clostrid-
ium diﬃcile-associated enteric disease,” Annals of Internal
Medicine, vol. 145, no. 10, pp. 758–764, 2006.
[ 3 ]J .F r e e m a n ,M .P .B a u e r ,S .D .B a i n e se ta l . ,“ T h ec h a n g -
ing epidemiology of Clostridium diﬃcile infections,” Clinical
Microbiology Reviews, vol. 23, no. 3, pp. 529–549, 2010.
[4] B.Razavi,A.Apisarnthanarak,andL.M.Mundy,“Clostridium
diﬃcile: emergence of hypervirulence and ﬂuoroquinolone
resistance,” Infection, vol. 35, no. 5, pp. 300–307, 2007.
[5] S. O. Ali, J. P. Welch, and R. J. Dring, “Early surgical inter-
vention for fulminant pseudomembranous colitis,” American
Surgeon, vol. 74, no. 1, pp. 20–26, 2008.
[ 6 ]J .C .B y r n ,D .C .M a u n ,D .S .G i n g o l d ,D .T .B a r i l ,J .J .O z a o ,
and C. M. Divino, “Predictors of mortality after colectomy for
fulminant Clostridium diﬃcile colitis,” Archives of Surgery, vol.
143, no. 2, pp. 150–155, 2008.
[7] M. M. Earhart, “The identiﬁcation and treatment of toxic
megacolon secondary to pseudomembranous colitis,” Dimen-
sions of Critical Care Nursing, vol. 27, no. 6, pp. 249–254, 2008.
[8] K. Gash, E. Brown, and A. Pullyblank, “Emergency subtotal
colectomy for fulminant Clostridium diﬃcile colitis—is a
surgical solution considered for all patients?” Annals of The
Royal College of Surgeons of England, vol. 92, no. 1, pp. 56–60,
2010.Gastroenterology Research and Practice 7
[ 9 ]J .F .H a l la n dD .B e r g e r ,“ O u t c o m eo fc o l e c t o m yf o rClostrid-
ium diﬃcile colitis: a plea for early surgical management,”
AmericanJournalofSurgery,vol.196,no.3,pp.384–388,2008.
[10] W. E. Longo, J. E. Mazuski, K. S. Virgo, P. Lee, A. N.
Bahadursingh, and F. E. Johnson, “Outcome after colectomy
for Clostridium diﬃcile colitis,” Diseases of the Colon and
Rectum, vol. 47, no. 10, pp. 1620–1626, 2004.
[11] J. G. Bartlett and D. N. Gerding, “Clinical recognition and
diagnosis of Clostridium diﬃcile infection,” Clinical Infectious
Diseases, vol. 46, supplement 1, pp. S12–S18, 2008.
[12] J. Suzanne, J. P. Miguet, J. P. Pageaut, P. Carayon, G.
Pageaut, and H. Gisselbrecht, “Rectoscopy: a useful tool to
diagnose pseudomembranous colitis (author’s translation),”
La Nouvelle Presse M´ edicale, vol. 7, no. 25, pp. 2245–2247,
1978.
[13] F. J. Tedesco, R. W. Barton, and D. H. Alpers, “Clindamycin
associated colitis. A prospective study,” Annals of Internal
Medicine, vol. 81, no. 4, pp. 429–433, 1974.
[14] J. M. Bergstein, A. Kramer, D. H. Wittman, C. Aprahamian,
andE.J.Quebbeman,“Pseudomembranouscolitis:howuseful
is endoscopy?” Surgical Endoscopy, vol. 4, no. 4, pp. 217–219,
1990.
[15] J. G. Bartlett, “Clostridium diﬃcile: progress and challenges,”
Annals of the New York Academy of Sciences, vol. 1213, no. 1,
pp. 62–69, 2010.
[16] J. P´ epin, L. Valiquette, M. E. Alary et al., “Clostridium diﬃcile-
associated diarrhea in a region of Quebec from 1991 to 2003:
a changing pattern of disease severity,” Canadian Medical
Association Journal, vol. 171, no. 5, pp. 466–472, 2004.
[17] C. M. Surawicz, “Antibiotics and Clostridium diﬃcile:c a u s e
and cure,” Journal of Clinical Gastroenterology,v o l .4 1 ,n o .1 ,
pp. 1–2, 2007.
[18] S. S. Johal, J. Hammond, K. Solomon, P. D. James, and
Y. R. Mahida, “Clostridium diﬃcile associated diarrhoea in
hospitalised patients: onset in the community and hospital
and role of ﬂexible sigmoidoscopy,” Gut,v o l .5 3 ,n o .5 ,p p .
673–677, 2004.
[19] D. B. Scheurer, L. S. Hicks, E. F. Cook, and J. L. Schnipper,
“Accuracy of ICD-9 coding for Clostridium diﬃcile infections:
ar e t r o s p e c t i v ec o h o r t , ”Epidemiology and Infection, vol. 135,
no. 6, pp. 1010–1013, 2007.
[20] D. N. Gerding and J. S. Brazier, “Optimal methods for
identifying Clostridium diﬃcile infections,” Clinical Infectious
Diseases, vol. 16, supplement 4, pp. S439–S442, 1993.
[21] J. Pepin, T. T. Vo, M. Boutros et al., “Risk factors for mortality
following emergency colectomy for fulminant Clostridium
diﬃcile infection,” Diseases of the Colon and Rectum, vol. 52,
no. 3, pp. 400–405, 2009.
[22] S. Sharma, A. Gurakar, C. Camci, and N. Jabbour, “Avoid-
ing pitfalls: what an endoscopist should know in liver
transplantation-part II,” Digestive Diseases and Sciences, vol.
54, no. 7, pp. 1386–1402, 2009.
[23] I. Stelzmueller, H. Goegele, M. Biebl et al., “Clostridium
diﬃcile colitis in solid organ transplantation—a single-center
experience,” Digestive Diseases and Sciences, vol. 52, no. 11, pp.
3231–3236, 2007.
[24] B. Yates, D. M. Murphy, A. J. Fisher et al., “Pseudomembra-
nous colitis in four patients with cystic ﬁbrosis following lung
transplantation,” Thorax, vol. 62, no. 6, pp. 554–556, 2007.
[25] T. Berdichevski, I. Barshack, S. Bar-Meir, and S. Ben-Horin,
“Pseudomembranesinapatientwithﬂare-upofinﬂammatory
bowel disease (IBD): is it only Clostridium diﬃcile or is it still
an IBD exacerbation?” Endoscopy, vol. 42, supplement 2, p.
E131, 2010.
[26] K. Nomura, Y. Fujimoto, M. Yamashita et al., “Absence of
pseudomembranes in Clostridium diﬃcile-associated diarrhea
in patients using immunosuppression agents,” Scandinavian
Journal of Gastroenterology, vol. 44, no. 1, pp. 74–78, 2009.
[27] B. Faris, A. Blackmore, and N. Haboubi, “Review of medical
and surgical management of Clostridium diﬃcile infection,”
Techniques in Coloproctology, vol. 14, no. 2, pp. 97–105, 2010.